Pancreatic Ductal Adenocarcinoma Pipeline Analysis

According to DelveInsight, over 80 key companies are actively engaged in developing more than 80 treatment therapies for Pancreatic Ductal Adenocarcinoma.

Pancreatic Ductal Adenocarcinoma Overview:

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of cancer, with a five-year survival rate below 10%. The majority of cases are diagnosed at a late stage—either unresectable or metastatic—contributing to its grim outlook. PDAC is a complex, multifactorial disease lacking effective early detection methods, as symptoms often appear only after the cancer has significantly advanced or spread.

Treatment is particularly difficult due to a combination of genetic and cellular challenges. Pancreatic tumors frequently exhibit a high level of genetic mutations, resulting in genomic instability, which significantly drives tumor progression and resistance to available therapies.

Request for a detailed insights report on Pancreatic Ductal Adenocarcinoma pipeline insights

“Pancreatic Ductal Adenocarcinoma Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pancreatic Ductal Adenocarcinoma Therapeutics Market.

Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report

• DelveInsight’s Pancreatic Ductal Adenocarcinoma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Pancreatic Ductal Adenocarcinoma treatment.

• In January 2025, Sanofi announced the results of its Phase III IRAKLIA trial evaluating Sarclisa (isatuximab) for Pancreatic Ductal Adenocarcinoma (MM). Conducted across 252 global sites, the trial involved 531 adult patients who had received at least one prior therapy, including lenalidomide and a proteasome inhibitor. The trial met its co-primary endpoints when Sarclisa was administered subcutaneously via an on-body delivery system (OBDS) in combination with pomalidomide and dexamethasone (Pd).

• In September 2024, Johnson & Johnson released findings from the Phase III CARTITUDE-4 trial, demonstrating that its cell therapy, CARVYKTI (ciltacabtagene autoleucel), significantly improved overall survival in Pancreatic Ductal Adenocarcinoma patients. The trial compared CARVYKTI to standard regimens such as pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) in patients previously treated with at least one therapy, including a proteasome inhibitor.

• In August 2024, Swiss biopharmaceutical company Opna Bio initiated a Phase I trial for OPN-6602, an EP300/CBP bromodomain inhibitor for Pancreatic Ductal Adenocarcinoma. The first dose was administered at The START Center for Cancer Research in Grand Rapids, Michigan, with plans to enroll up to 130 participants with relapsed or refractory MM at multiple U.S. sites.

• In April 2024, Bristol Myers Squibb and 2seventy bio announced the FDA’s approval of Abecma® (idecabtagene vicleucel; ide-cel) for adults with relapsed or refractory Pancreatic Ductal Adenocarcinoma after at least two prior therapies. These must include an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody. Based on the KarMMa-3 trial, this expanded approval allows earlier use for triple-class exposed patients. Abecma is administered as a single infusion, with a recommended dose range of 300 to 510 x 10⁶ CAR-positive T cells.

• Key Pancreatic Ductal Adenocarcinoma companies such as Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others are evaluating new drugs for Pancreatic Ductal Adenocarcinoma to improve the treatment landscape.

• Promising Pancreatic Ductal Adenocarcinoma pipeline therapies in various stages of development include Onvansertib, Nadunolimab, and others.

Pancreatic Ductal Adenocarcinoma Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Pancreatic Ductal Adenocarcinoma Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Ductal Adenocarcinoma treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Pancreatic Ductal Adenocarcinoma market.

Download our free sample page report on Pancreatic Ductal Adenocarcinoma pipeline insights

Pancreatic Ductal Adenocarcinoma Emerging Drugs

• Onvansertib: Cardiff Oncology

• Nadunolimab: Cantargia

• Zimberelimab: Arcus Biosciences

Pancreatic Ductal Adenocarcinoma Companies

Over 80 companies are currently focused on developing treatments for Pancreatic Ductal Adenocarcinoma. Among these, XOMA leads with a drug candidate that has progressed to the most advanced stage—Phase III of clinical development.

DelveInsight’s report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Pancreatic Ductal Adenocarcinoma Therapies and Key Companies: Pancreatic Ductal Adenocarcinoma Clinical Trials and advancements

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutic Assessment

• Pancreatic Ductal Adenocarcinoma Assessment by Product Type

• Pancreatic Ductal Adenocarcinoma By Stage

• Pancreatic Ductal Adenocarcinoma Assessment by Route of Administration

• Pancreatic Ductal Adenocarcinoma Assessment by Molecule Type

Download Pancreatic Ductal Adenocarcinoma Sample report to know in detail about the Pancreatic Ductal Adenocarcinoma treatment market @ Pancreatic Ductal Adenocarcinoma Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Pancreatic Ductal Adenocarcinoma Current Treatment Patterns

4. Pancreatic Ductal Adenocarcinoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Pancreatic Ductal Adenocarcinoma Late-Stage Products (Phase-III)

7. Pancreatic Ductal Adenocarcinoma Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Pancreatic Ductal Adenocarcinoma Discontinued Products

13. Pancreatic Ductal Adenocarcinoma Product Profiles

14. Pancreatic Ductal Adenocarcinoma Key Companies

15. Pancreatic Ductal Adenocarcinoma Key Products

16. Dormant and Discontinued Products

17. Pancreatic Ductal Adenocarcinoma Unmet Needs

18. Pancreatic Ductal Adenocarcinoma Future Perspectives

19. Pancreatic Ductal Adenocarcinoma Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Pancreatic Ductal Adenocarcinoma Pipeline Reports Offerings

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/